XML 71 R49.htm IDEA: XBRL DOCUMENT v3.24.4
Schedule of Error Corrections And Prior Period Adjustments (Details) - USD ($)
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2022
Aug. 01, 2022
Sep. 30, 2024
Jun. 30, 2024
Mar. 31, 2024
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Additional paid in capital     $ 31,664,226     $ 29,402,533 [1]     $ 31,664,226 $ 29,402,533 [1] $ 29,489,055 $ 26,518,433 $ 12,063,940
Additional paid in capital     (32,979,632)     (23,792,804)     (32,979,632) (23,792,804) (25,433,304) (18,840,581) (13,844,512)
Research and development, net of contract expense reimbursements     1,400,564     1,045,177     2,632,387 2,806,644 3,517,093 1,047,385  
General and administrative     328,995     265,553     963,642 730,186 1,046,854 473,714  
Legal and professional     1,322,002     288,416     2,323,013 1,072,728 1,328,435 822,727  
Net loss from operations     (3,051,561)     (1,599,146)     (5,919,042) (4,609,558) (5,892,382) (2,343,826)  
Interest expenses           (623,465)       (1,952,147)      
Financing fee             (104,245) (104,245) (189,912)  
Change in fair value of derivative liabilities     $ 286,316     $ 442,900     $ 340,405 $ 2,118,175 2,216,488 (189,000)  
Change in fair value of warrant liabilities   $ (146,624)                 (398,675)  
Loss on extinguishment of debt $ 1,531,852                     (1,795,652)  
Net loss                       (4,996,069)  
Dividend on Series A Preferred Stock                     (402,064)  
Deemed dividend on extinguishment of Series A Preferred Stock                       (439,427)  
Deemed dividend on modification of equity-classified warrants, as restated                       (941,000)  
Deemed contribution on conversion of preferred stock and settlement of preferred stock dividends, as restated                       31,423  
Net loss attributable to common stockholders                     $ (6,592,723) $ (6,747,137)  
Net loss per shares - Basic     $ (1.59)     $ (0.91)     $ (3.45) $ (2.72) $ (3.53) $ (5.04)  
Net loss per shares - Diluted     $ (1.59)     $ (0.91)     $ (3.45) $ (2.72) $ (3.53) $ (5.04)  
Common stock issued for cash upon initial public offering and exercise of warrants, net of issuance costs, as restated $ 2,031,250                     $ 9,951,356 2,031,249
Common stock issued for cash                        
Warrants exercised for cash                        
Warrants issued for financing costs               $ 90,816     $ 90,816 14,662  
Common stock issued for conversion of accrued interest                        
Common stock issued upon conversion of convertible debt and exercise of related warrants     $ 1,621,996     $ 429,310           1,199,916  
Common stock issued for exercise of warrants with settlement of notes payable                       2,153,124  
Stock-based compensation     45,275 $ 71,162 $ 111,449 37,583 $ 49,522 8,333     181,960 237,547  
Dividends on Series A preferred stock                       (402,064)  
Common shares issued for dividends on and conversion of Series A preferred stock                       402,064  
Reclassification of fair value of warrant liability to equity upon initial public offering                     881,553  
Net loss     (3,784,082) $ (2,031,215) $ (1,731,031) (1,792,754) $ (2,184,372) (975,097) $ (7,546,328) $ (4,952,223) (6,592,723) (4,996,069)  
Change in fair value of derivative liabilities     (286,316)     (442,900)     (340,405) (2,118,175) (2,216,488) 189,000  
Change in fair value of warrant liabilities   $ 146,624                 398,675  
Amortization of debt discount and finance fees                 1,079,444 1,654,724 2,123,049 377,384  
Loss on settlement of convertible debt     $ 762,186     43,414     833,501 477,221 477,221 1,795,652  
Fair value of freestanding instruments in excess of proceeds                     189,912  
Gain on interest relief on conversion of notes payable                        
Stock-based compensation                 227,886 95,438 181,960 237,547  
Accrued interest payable                 (15,056) 106,578 110,453 18,378  
Net cash used in operating activities                 (4,637,068) (4,518,973) (5,581,147) (2,666,411)  
Proceeds from issuance of common shares and warrants                     9,995,513  
Proceeds from convertible notes payable                 3,935,000 3,935,000 550,715  
Proceeds from notes payable and warrants                     50,000  
Payment for finance costs related to convertible notes payable                 (345,000) (345,000) (17,363)  
Net cash provided by (used in) financing activities                 (698,457) 2,904,527 2,570,083 10,578,865  
Common stock issued upon conversion of convertible debt                       1,199,916  
Common stock issued for exercise of warrants with settlement of notes payable                     $ 2,153,124  
Common shares issued for dividends on and conversion of Series A preferred stock                     402,064  
Warrants issued for financing fees, net of issuance fees of $8,727 and $0, respectively                 90,816 $ 90,816 $ 14,662  
Warranst of issuance fees               $ 8,727 $ 0 8,727 8,727 0  
Nonrelated Party [Member]                          
Interest expenses                       (428,688)  
Previously Reported [Member]                          
Additional paid in capital           19,456,841 [1]       19,456,841 [1] 19,543,363 16,572,741 4,150,948
Additional paid in capital           (13,847,112)       (13,847,112) (15,487,612) (8,894,889) (5,795,432)
Research and development, net of contract expense reimbursements                   3,084,488   1,148,712  
General and administrative                   452,342   538,796  
Legal and professional                       866,770  
Net loss from operations                       (2,554,278)  
Financing fee                        
Change in fair value of derivative liabilities                        
Change in fair value of warrant liabilities                       94,025  
Loss on extinguishment of debt                        
Net loss                       (3,028,448)  
Dividend on Series A Preferred Stock                       (71,009)  
Deemed dividend on extinguishment of Series A Preferred Stock                        
Deemed dividend on modification of equity-classified warrants, as restated                        
Deemed contribution on conversion of preferred stock and settlement of preferred stock dividends, as restated                        
Net loss attributable to common stockholders                       $ (3,099,457)  
Net loss per shares - Basic                       $ (2.32)  
Net loss per shares - Diluted                       $ (2.32)  
Common stock issued for cash upon initial public offering and exercise of warrants, net of issuance costs, as restated                        
Common stock issued for cash                       10,008,095  
Warrants exercised for cash                       14,098  
Warrants issued for financing costs                       412,241  
Common stock issued for conversion of accrued interest                       588,524  
Common stock issued upon conversion of convertible debt and exercise of related warrants                        
Common stock issued for exercise of warrants with settlement of notes payable                       576,476  
Stock-based compensation                       403,956  
Dividends on Series A preferred stock                       (71,009)  
Common shares issued for dividends on and conversion of Series A preferred stock                       402,068  
Reclassification of fair value of warrant liability to equity upon initial public offering                        
Net loss                       (3,028,448)  
Change in fair value of derivative liabilities                        
Change in fair value of warrant liabilities                       (94,025)  
Amortization of debt discount and finance fees                       885,505  
Loss on settlement of convertible debt                        
Fair value of freestanding instruments in excess of proceeds                        
Gain on interest relief on conversion of notes payable                       12,625  
Stock-based compensation                       403,956  
Accrued interest payable                       (13,177)  
Net cash used in operating activities                       (2,710,454)  
Proceeds from issuance of common shares and warrants                       10,022,193  
Proceeds from convertible notes payable                       600,715  
Proceeds from notes payable and warrants                        
Payment for finance costs related to convertible notes payable                        
Net cash provided by (used in) financing activities                       10,622,908  
Common stock issued upon conversion of convertible debt                       588,524  
Common stock issued for exercise of warrants with settlement of notes payable                       $ 576,476  
Common shares issued for dividends on and conversion of Series A preferred stock                       402,068  
Warrants issued for financing fees, net of issuance fees of $8,727 and $0, respectively                       $ 412,241  
Previously Reported [Member] | Nonrelated Party [Member]                          
Interest expenses                       (917,879)  
Revision of Prior Period, Reclassification, Adjustment [Member]                          
Additional paid in capital           9,945,692 [1]       9,945,692 [1] 9,945,692 9,945,692 [2] 7,912,992 [3]
Additional paid in capital           $ (9,945,692)       (9,945,692) $ (9,945,692) (9,945,692) [4] $ (8,049,080) [5]
Research and development, net of contract expense reimbursements                   (277,844)   (101,327)  
General and administrative                   $ 277,844   (65,082)  
Legal and professional                       (44,043)  
Net loss from operations                       210,452  
Financing fee                       (189,912)  
Change in fair value of derivative liabilities                       (189,000)  
Change in fair value of warrant liabilities                       (492,700)  
Loss on extinguishment of debt                       (1,795,652)  
Net loss                       (1,967,621)  
Dividend on Series A Preferred Stock                       (331,055)  
Deemed dividend on extinguishment of Series A Preferred Stock                       (439,427)  
Deemed dividend on modification of equity-classified warrants, as restated                       (941,000)  
Deemed contribution on conversion of preferred stock and settlement of preferred stock dividends, as restated                       31,423  
Net loss attributable to common stockholders                       $ (3,647,680)  
Net loss per shares - Basic                       $ (2.72)  
Net loss per shares - Diluted                       $ (2.72)  
Common stock issued for cash upon initial public offering and exercise of warrants, net of issuance costs, as restated                       $ 9,951,356  
Common stock issued for cash                       (10,008,095)  
Warrants exercised for cash                       (14,098)  
Warrants issued for financing costs                       (397,579)  
Common stock issued for conversion of accrued interest                       (588,524)  
Common stock issued upon conversion of convertible debt and exercise of related warrants                       1,199,916  
Common stock issued for exercise of warrants with settlement of notes payable                       1,576,648  
Stock-based compensation                       (166,409)  
Dividends on Series A preferred stock                       (331,055)  
Common shares issued for dividends on and conversion of Series A preferred stock                       (4)  
Reclassification of fair value of warrant liability to equity upon initial public offering                       881,553  
Net loss                       (1,967,621)  
Change in fair value of derivative liabilities                       189,000  
Change in fair value of warrant liabilities                       492,700  
Amortization of debt discount and finance fees                       (508,121)  
Loss on settlement of convertible debt                       1,795,652  
Fair value of freestanding instruments in excess of proceeds                       189,912  
Gain on interest relief on conversion of notes payable                       (12,625)  
Stock-based compensation                       (166,409)  
Accrued interest payable                       31,555  
Net cash used in operating activities                       44,043  
Proceeds from issuance of common shares and warrants                       (26,680)  
Proceeds from convertible notes payable                       (50,000)  
Proceeds from notes payable and warrants                       50,000  
Payment for finance costs related to convertible notes payable                       (17,363)  
Net cash provided by (used in) financing activities                       (44,043)  
Common stock issued upon conversion of convertible debt                       611,392  
Common stock issued for exercise of warrants with settlement of notes payable                       $ 1,576,648  
Common shares issued for dividends on and conversion of Series A preferred stock                       (4)  
Warrants issued for financing fees, net of issuance fees of $8,727 and $0, respectively                       $ (397,579)  
Revision of Prior Period, Reclassification, Adjustment [Member] | Nonrelated Party [Member]                          
Interest expenses                       $ 489,191  
[1] The Reverse Stock Split (Note 1) also resulted in an adjustment to the condensed consolidated balance sheet for the period ended September 30, 2023 with an increase to additional paid in capital of $140 and an offsetting adjustment to the carrying value of common stock.
[2] Adjustments include corrections for stock compensation errors (increase of $7,843,052); recognition of Series A Preferred Stock accrued dividends (decrease of $402,064); correction of issuance cost recognition related to financing transactions (decrease of $174,082); corrections to the Company’s initial classification and recognition of warrants issued in financing transactions (decrease of $416,266), reclassifications of warrants from liability to equity (increase of $881,554); correction in the application of extinguishment accounting upon settlement of debt instruments (increase of $2,213,498).
[3] Adjustments include adjustment to the carrying value of notes payable, including recognition of day 1 loss (decrease of $7,351); identification of costs to be recorded against Series A Preferred Stock carrying value (decrease of 89,118); and stock compensation adjustments (increase of $8,009,461).
[4] Adjustments include corrections for stock compensation errors (increase of $8,009,461); adjustment of the estimated Series A Preferred Stock warrant obligation fair value (increase of $240,930); reversal of accrued Series A Preferred Stock dividends (decrease of $402,064); recognition of bifurcated derivatives and recording of loss at issuance (increase of $296,151); correction of issuance cost recognition related to financing transactions (decrease of $166,407); and the aggregate adjustments to 2022 net loss as detailed below (increase of $1,967,621).
[5] Adjustments include reversal of dividend liability recorded (decrease of $331,059); identification of deferred IPO costs (decrease of ($55,182); identification of costs to be recorded against Series A Preferred Stock carrying value (decrease of 89,118); adjustment to the estimated fair value of warrant liability (increase of $240,930); adjustment to the carrying value of notes payable, including recognition of day 1 loss (increase of $274,048); and stock compensation adjustments (increase of $8,009,461).